摘要
目的探讨恩替卡韦联合康艾注射液治疗乙型肝炎病毒(HBV)相关性中晚期肝癌的临床疗效,以期为HBV相关性中晚期肝癌的治疗提供参考。方法选取HBV相关性中晚期肝癌患者60例,按简单数字法随机分为观察组和对照组,各30例。对照组单纯采用康艾注射液治疗,观察组采用恩替卡韦联合康艾注射液治疗,观察比较二组生存质量提高效果、肝功能指标、凝血功能指标、HBV-DNA载量及AFP水平。结果观察组生存质量提高总有效率为86.66%,对照组总有效率为53.34%,观察组疗效优于对照组(P<0.05);观察组GPT、AST、TBil、ALB肝功能指标改善显著优于对照组(P<0.01);观察组PT、APPT、TT、FIB凝血功能指标改善显著优于对照组(P<0.01);观察组HBV-DNA载量及AFP水平均下降要优于对照组(P<0.05)。结论恩替卡韦联合康艾注射液治疗HBV相关性中晚期肝癌的临床疗效显著,具有安全、有效等特点,值得临床进一步研究应用。
Objective To investigate the clinical efficacy of entecavir joint Kang＆#39;ai injection in the treatment of HBV-related liver cancer in advanced,in order to provide a reference for advanced treatment of the diseas.Methods Totally 60 cases of HBV correlation with advanced liver cancer patients were selected from September 2012 to November 2013 in author＆#39;s hospital,according to simple numbers were randomly＆amp;nbsp;divided into treatment group and control group,30 cases in each group.Control group was treated with Kang＆#39;ai injection,treatment group received entecavir joint Kang＆#39;ai injection therapy,the effect of improving the quality of life,liver function,coagulation parameters,HBV- DNA load and AFP levels in the two groups were observed and compared.Results The total effective rate on quality of life improved was 86. 66%,53.34% forthe control group,the former was better than the latter（P 〈0.05）.The indicators of liver function such as GPT,AST,TBil,ALB were significant improvement in the treatment group than the control group （P 〈0.01）;same results were in PT,APPT,TT,FIB coagulation parameters improve-ment significantly （P 〈0.01）.But HBV-DNA load and AFP levels in the treatment group were decreased superior than the control group （P 〈0.05）.Conclusion Entecavir therapy joint Kang＆#39;ai injection are effec-tive,safe and worthy of further clinical applications in the treatment of patients with advanced hepatocellu-lar carcinoma related to HBV-infection.
出处
《中国煤炭工业医学杂志》
2015年第4期576-579,共4页
Chinese Journal of Coal Industry Medicine
